Compare PAGP & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAGP | FOLD |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | 3900 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.5B |
| IPO Year | 2013 | 2006 |
| Metric | PAGP | FOLD |
|---|---|---|
| Price | $24.19 | $14.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $21.78 | ★ $27.25 |
| AVG Volume (30 Days) | 1.8M | ★ 2.7M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 7.01% | N/A |
| EPS Growth | ★ 370.00 | 50.00 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $44,262,000,000.00 | N/A |
| Revenue This Year | $12.42 | $20.50 |
| Revenue Next Year | N/A | $18.59 |
| P/E Ratio | $88.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.61 | $5.66 |
| 52 Week High | $24.76 | $14.46 |
| Indicator | PAGP | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 61.41 | 71.78 |
| Support Level | $18.53 | $14.21 |
| Resistance Level | $24.76 | N/A |
| Average True Range (ATR) | 0.46 | 0.02 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 61.06 | 90.00 |
Plains GP Holdings LP owns and operates midstream energy infrastructure and provides logistics services for crude oil, natural gas liquids (NGL), and natural gas. The group manages its operations through two operating segments: Crude Oil segment operations generally consist of gathering and transporting crude oil using pipelines (including gathering systems), trucks, and, at times, on barges or railcars; and NGL segment operations involve NGL storage and terminalling from NGL assets located in the Southwestern United States. It generates the majority of its revenue from the Crude Oil segment. Its geographic markets are the United States and Canada. It generates the majority of its revenue from the United States.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.